The Apex Times
Above the Noise
Business Wire
BusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex TimesBusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex TimesBusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex TimesBusinessLockheed Martin pursues U.S. mineral supply deals tied to broader defense supply-chain push, sources sayThe Apex TimesBusinessPalantir shares rise after clearing the 200-day moving average, a chart milestone that traders watch closelyThe Apex TimesBusinessApple says memory supply constraints are likely to keep tightening, pointing to limits on advanced-chip productionThe Apex TimesBusinessMarket sentiment firms as investors watch after-hours results, with AMD in focus alongside SpaceX and Booking.comThe Apex TimesBusinessYahoo Finance highlights Wall Street’s upbeat read on Coca-Cola using an average brokerage recommendation metricThe Apex TimesBusinessUber’s Q2 update spotlights the metrics investors will watch nextThe Apex TimesBusinessDisney’s latest quarter shows how results stacked up against Wall Street expectations, with several key metrics in focusThe Apex TimesBusinessUber retreats after outlook outlines caution, even as earnings and bookings top viewsThe Apex TimesBusinessAMD slides 6% after record quarter as NVIDIA rises on SpaceX-related deal chatterThe Apex TimesBusinessTim Cook warns memory prices should keep rising, indicating a changing cost backdrop for AppleThe Apex TimesBusinessPalantir shares jump after earnings as a veteran analyst outlines renewed optimismThe Apex TimesBusinessSpotify shares fall after investor focus shifts from subscriber milestone to earnings and spendingThe Apex Times
Back to front
Eli Lilly CEO points to retatrutide as next wave after Mounjaro and Zepbound propel quarterly jump
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 5, 9:46 AM EDT

Eli Lilly CEO points to retatrutide as next wave after Mounjaro and Zepbound propel quarterly jump

Stronger-than-expected results led Lilly’s leadership to look beyond its current weight-loss franchise, with CEO David Ricks citing retatrutide as a potential next growth driver.

2 min readEditor-approved Apex article

Eli Lilly’s second-quarter results showed what the company’s weight-loss medicines are already doing for sales, and CEO David Ricks used the update to argue that the next chapter could come from retatrutide.

According to the report, Lilly’s revenue rose 48% in the quarter, and the company’s performance exceeded Wall Street expectations. The upside was attributed primarily to continued demand for Mounjaro and Zepbound, Lilly’s two widely used drugs for weight management and metabolic disease.

Mounjaro and Zepbound are part of Lilly’s rapidly expanding portfolio in the obesity and related-care space. In the marketplace, demand has been a central driver of revenue momentum for manufacturers developing incretin-based therapies, where patients, payers, and healthcare systems are trying to manage both chronic conditions and long-term costs.

Beyond the current franchise, Ricks indicated confidence in retatrutide, an investigational weight-loss medicine. In the post, he positioned retatrutide as a potential growth engine after the company’s established products have already scaled.

The CEO’s comments framed Lilly’s outlook in unusually emphatic terms, stating the company’s future had “never been brighter.” The message suggests Lilly sees sufficient opportunity to extend its obesity leadership beyond its near-term commercialization pipeline.

While the report does not provide detailed clinical, regulatory, or timeline information about retatrutide, the thrust of the message is clear: Lilly wants investors and partners to focus not only on current Mounjaro and Zepbound demand, but also on the possibility that a broader set of weight-loss options could drive additional growth.

Industry context matters here because obesity drug markets are increasingly competitive and shaped by both efficacy data and manufacturing scale. When revenue beats come primarily from a single therapeutic area, companies often use earnings communications to confirm that they have follow-on assets that could sustain growth as demand, pricing, and competition evolve.

Still, several specifics are not disclosed in the post itself, including any trial phase commentary, regulatory status, or target milestones for retatrutide. Investors will likely need to look to future Lilly filings, investor presentations, or trial updates for the details that determine whether retatrutide can move from promise to another commercial pillar.

Why It Matters

  • Lilly’s results reinforce that its current weight-loss franchise is still a major earnings driver.
  • Management’s emphasis on retatrutide highlights how companies in obesity drugs are planning for the next product cycle, not just near-term sales.
  • For investors and payers, follow-on pipeline assets can affect expectations for future pricing, availability, and competitive dynamics.
  • The comments increase attention on retatrutide’s progress, even though the post does not provide detailed timing or regulatory milestones.

Sources

Key Facts

  • Eli Lilly reported second-quarter revenue growth of 48%.
  • The report says Lilly’s quarterly results beat Wall Street estimates.
  • The revenue strength was attributed primarily to demand for Mounjaro and Zepbound.
  • CEO David Ricks said Lilly is betting on retatrutide as a next growth driver.
  • Ricks characterized the company’s future as “never been brighter.”

Healthcare Related

Aug 5, 10:00 AM EDT
The Apex Times

Eli Lilly’s weight-loss lineup keeps pulling the results, again

Investors are watching Eli Lilly’s demand momentum for Zepbound and Mounjaro as the company’s latest reporting reinforced a strong earnings performance and a higher sales outlook, according to a Yahoo Finance report.

Eli Lilly’s weight-loss lineup keeps pulling the results, again
The Apex Times
Eli Lilly CEO points to retatrutide as next wave after Mounjaro and Zepbound propel quarterly jump | The Apex Times